223556-42-1

Basic information

• Product Name: 4-(5-BROMO-PYRIDIN-2-YL)-THIOMORPHOLINE
• Synonyms: 4-(5-BROMO-PYRIDIN-2-YL)-THIOMORPHOLINE
• CAS NO: 223556-42-1
• Molecular Formula: C9H11BrN2S
• Molecular Weight: 259.16604
• Mol File: 223556-42-1.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 4-(5-BROMO-PYRIDIN-2-YL)-THIOMORPHOLINE(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(5-BROMO-PYRIDIN-2-YL)-THIOMORPHOLINE(223556-42-1)
• EPA Substance Registry System: 4-(5-BROMO-PYRIDIN-2-YL)-THIOMORPHOLINE(223556-42-1)

Safety Data

• Hazardous Substances Data: 223556-42-1(Hazardous Substances Data)

Upstream product

• 123-90-0 Thiomorpholin 
• 53939-30-3 5-bromo-2-chloropyridine 
• 223463-13-6 2-iodo-5-bromopyridine 

Downstream Products

• 1202243-02-4 C₁₅H₁₄Cl₂N₂S*ClH 

Relevant articles and documents

NOVEL COMPOUNDS AS NADPH OXIDASE INHIBITORS

The present invention is related to new compounds, pharmaceutical composition thereof and to their use for the treatment and/or prophylaxis of disorders or conditions related to Nicotinamide adenine dinucleotide phosphate oxidase (NADPH Oxidase).

Inverting Conventional Chemoselectivity in Pd-Catalyzed Amine Arylations with Multiply Halogenated Pyridines

A new catalyst system capable of selective chloride functionalization in the Pd-catalyzed amination of 3,2- and 5,2- Br/Cl-pyridines is reported. A reaction optimization strategy employing ligand parametrization led to the identification of 1,1′-bis[bis(dimethylamino)phosphino]ferrocene "DMAPF", a readily available yet previously unutilized diphosphine, as a uniquely effective ligand for this transformation.

ANTI-MALIGNANT TUMOR AGENT COMPOSITION

To provide a satisfactory anticancer agent composition suppressing the growth of cancer (malignant tumor) reliably and hardly causing side effects, the present invention is directed to an anticancer agent composition including the following agents as active ingredient; a LAT1 inhibitor, and one or more agents selected from the group consisting of an alkylating agent, a platinum-based antineoplastic agent, an anti-metabolite, a topoisomerase inhibitor, an anti-microtubule polymerizing agent, a hormonal agent, an anti-microtubule depolymerizing agent, an anticancer antibiotic, and a molecular targeted agent.

N- (HETERO)ARYL, 2- (HETERO)ARYL-SUBSTITUTED ACETAMIDES FOR USE AS WNT SIGNALING MODULATORS

The present invention relates to compounds of formulae 1 and 2 and methods for modulating the Wnt signaling pathway using these compounds, wherein A1, A2, B, Y and Z all represent rings.

AROMATIC AMINO ACID DERIVATIVES AND MEDICINAL COMPOSITIONS

An aromatic amino acid derivative represented by the formula ( I ) or its pharmacologically acceptable salt: wherein,R1 is a hydrogen atom or an amino-protecting group,R2 is a halogen atom or an alkyl, aralkyl or aryl group,R3 is 1○ a hydrogen atom, 2○ an aroylamino group, 3○ a phenyl group substituted with lower alkyl, phenyl, phenoxy, etc. 4○ a naphthyl or tetrahydronaphthyl group optionally substituted with hydroxy, lower alkoxy or di(lower)alkylamino, 5○ an unsaturated mono-cyclic heterocyclic group containing N, O and/or S substituted with lower alkyl, phenyl, naphthyl or tetrahydroquinolyl, 6○ an unsaturated or partially saturated condensed heterocyclic group containing N, O and/or S, optionally substituted with oxo, carboxy, amino, lower alkyl, etc.; X is a halogen atom, an alkyl group or an alkoxy group; Y is oxygen atom or nitrogen atom; 1 is 0 or 1; m is 0, 1 or 2; n is an integer of 0-5. This compound can inhibit a transporter (LAT1) of essential amino acid which is one of main nutrition for cancer cells and accordingly cause drain of the essential amino acid on the cancer cells and finally can prohibit the multiplication of cancer cells.